Latest Strattera news
Many Patients Don’t Reach Target Dose of Atomoxetine
posted August 10th
by modernClinician Editorial Team
by modernClinician Editorial Team
A considerable proportion of patients receiving atomoxetine (ATX), especially those receiving ATX monotherapy, do not reach the recommended dose of 80 mg/day, according to a study published online July 31 in CNS Neuroscience & Therapeutics.
Atomoxetine Use Doesn’t Up Suicide Risk in Children
posted April 27th
by modernClinician Editorial Team
by modernClinician Editorial Team
Treatment with the selective noradrenalin-reuptake-inhibitor atomoxetine is not associated with increased suicide risk compared with stimulant use in children and adolescents, according to a study published online April 26 in Pediatrics.
Editor's Recommendations
Children, Teens Have Higher Psychological Burden of Atopic Dermatitis 
Proportion of ED Visits for Suspected Suicide Down From 2021 to 2025 
Tourette Syndrome Takes High Toll on Physical, Mental, Financial Well-Being 
Homicide, Suicide, and Overdose Leading Causes of Maternal Death Related Articles
Onset of Mortality, Morbidity Delayed for Offspring of Centenarians 
Antenatal Complications Increased With Maternal Multiple Long-Term Conditions 
Insurance Poses Barrier to Virtual Pulmonary Rehabilitation for COPD 
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders Monthly Specialist Briefings
Stay Connected
